Biomm S.A.

São Paulo Stock Exchange BIOM3.SA

Biomm S.A. Operating Income for the year ending December 31, 2023: USD -14.92 M

Biomm S.A. Operating Income is USD -14.92 M for the year ending December 31, 2023, a -0.34% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Biomm S.A. Operating Income for the year ending December 31, 2022 was USD -14.87 M, a -26.96% change year over year.
Biomm S.A. Operating Income for the year ending December 31, 2021 was USD -11.71 M, a -3.07% change year over year.
Biomm S.A. Operating Income for the year ending December 31, 2020 was USD -11.36 M, a -1.48% change year over year.
Biomm S.A. Operating Income for the year ending December 31, 2019 was USD -11.20 M, a -18.69% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

São Paulo Stock Exchange: BIOM3.SA

Biomm S.A.

CEO	Mr. Heraldo Carvalho Marchezini
IPO Date	Jan. 11, 2000
Location	Brazil
Headquarters	Rua dos Pinheiros, 610
Employees	130
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; CONFORT CARE, a moisturizing foot cream; GLARGILIN, a glargine insulin; and HERZUMA, a trastuzumab. Biomm S.A. was founded in 2001 and is based in São Paulo, Brazil.

Key trends

Past 5 years